Euro
USD
British Pound
NULL
Product Description
MAP2K2 Monoclonal Antibody | E-AB-22162 | Elabscience
Type: Monoclonal Antibody
Synonyms: Cardiofaciocutaneous syndrome, CFC syndrome, CFC4, Dual specificity mitogen activated protein kinase kinase 2, Dual specificity mitogen-activated protein kinase kinase 2, ERK activator kinase 2, FLJ26075, MAP kinase kinase 2, map2k2, MAPK / ERK kinase 2, MAPK/ERK kinase 2, MAPKK 2, MAPKK2, MEK 2, MEK2, Microtubule associated protein kinase kinase 2, Mitogen activated protein kinase kinase 2, Mitogen activated protein kinase kinase 2 p45, MKK 2, MKK2, MP2K2, OTTHUMP00000165826, OTTHUMP00000165827, PRKMK 2, PRKMK2
Application: WB
Reactivity: Human, Mouse, Rat
Host: Mouse
Isotype: IgG
Reserch Areas: Cancer, Signal Transduction
Background: The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, mental retardation, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene.
Concentration: 1 mg/mL
Storage: Store at -20°C. Avoid freeze / thaw cycles.
Immunogen: Synthesized peptide derived from human MEK-2 around the non-phosphorylation site of T394.
Buffer: PBS with 0.02% sodium azide, 0.5% BSA and 50% glycerol, pH7.4
Purification Method: Protein A purification
Dilution: WB 1:500-1:2000, IHC 1:100-1:300, IP 1:200-1:500, ELISA 1:10000
Clone: N/A
Conjugation: Unconjugated
Molecular Weight(Calculated): N/A
Molecular Weight(Observed): 45 kDa
